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Abstract We have recently developed an in vitro differentiation
model of immortalized non-transformed human hepatocytes
using butyrate, and observed the induction of inducible NO
synthase (iNOS). In this study, we analyzed the effect of NO on
the urea-synthetic capacity of these cells. The inhibition of iNOS
during butyrate treatment significantly increased the urea-
synthetic capacity as compared to that of butyrate treatment
alone, possibly through the further induction of ornithine
transcarbamylase expression. Therefore, the inhibition of NO
production might be useful for obtaining more differentiated
hepatocytes in the process of in vitro induction of hepatocyte-
specific differentiation.
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1. Introduction
Nitric oxide (NO) has been identi¢ed as an important sig-
naling molecule in the liver. Experimental results of its e¡ect
on urea-synthetic capacity, one of the most important hepa-
tocyte-speci¢c functions and essential for the development of
an e⁄cient bioarti¢cial liver, are contradictory [1,2]. In animal
experiments, NO has demonstrated a capacity to either reduce
or increase the rate of urea synthesis of hepatocytes [1,2],
implying inter-strain and inter-species di¡erences in the NO-
mediated metabolic responses [3,4]. However, this e¡ect has
not yet been evaluated in non-transformed hepatocytes of
human origin.
We have recently developed an in vitro di¡erentiation mod-
el of immortalized non-transformed human hepatocytes using
butyrate, that is applicable to an arti¢cial liver device [5,6].
Speci¢cally, we have observed that butyrate treatment in-
creases the urea-synthetic capacity (ammonia-detoxifying
function) as well as the simultaneous growth arrest. Addition-
ally, the expression of inducible NO synthase (iNOS) mRNA
is increased in the butyrate-treated cells. The present study
was conducted to investigate the mechanism of iNOS induc-
tion by butyrate and the e¡ect of the increased NO produc-
tion during the process of di¡erentiation on the urea-synthetic
capacity of these cells.
2. Materials and methods
2.1. Chemicals
Ham’s F-12 medium, insulin, transferrin, hydrocortisone, L-gluta-
mine, CuSO4W5H2O, H2SeO3, ZnSO4W7H2O, glucagon, growth hor-
mone, linoleic acid, sodium butyrate (SB), nitro-L-arginine methyl
ester (L-NAME), aminoguanidine (AG), nitrate reductase from soy-
bean seedlings, MOPS, EDTA, NADH, sulfanilamide, phosphoric
acid, naphthylethylene diamine, genistein, NH4Cl, ornithine, carbam-
yl phosphate, triethanolamine and citrulline were purchased from
Sigma, St. Louis, MO, USA. Epidermal growth factor (EGF) was
obtained form Collaborative Biomedical, Waltham, MA, USA, and
sodium nitroprusside (SNP) was obtained from Merck, Darmstadt,
Germany.
2.2. Cell culture
The immortalized human hepatocytes [5,6] were maintained over
150 passages in a chemically de¢ned Ham’s F-12 medium containing
50 ng/ml EGF, 10 Wg/ml insulin, 5 Wg/ml transferrin, 3.5 WM hydro-
cortisone, 2 mM glutamine, 0.1 WM CuSO4W5H2O, 0.03 WM H2SeO3,
0.5 nM ZnSO4W7H2O, 1 ng/ml glucagon, 6.5 ng/ml growth hormone
and 0.5 Wg/ml linoleic acid. Cells were seeded at 8U104/ml into each
well of Primaria0 multiplates (Falcon Labware, Oxnard, CA, USA)
and incubated at 37‡C in 5% CO2. After 24 h, the medium was
replaced by fresh medium either with 5 mM of SB, or without as a
control. To inhibit iNOS, either L-NAME (3 mM) or AG (1 mM) was
used. The e¡ect of an exogenous NO donor (SNP, 0.5 mM) was also
analyzed.
2.3. RT-PCR for iNOS, urea cycle enzymes and hepatocyte
transcription factors
Total RNA was extracted from cells by the acid guanidinium thi-
ocyanate^phenol^chloroform method. Complementary DNA was syn-
thesized using 1 Wg RNA and random hexamer primers. The PCR
ampli¢cation of the complementary DNA was conducted in a reaction
mixture containing 20 pmol of each primer set (iNOS [7], 5P-CGG-
TGCTGTATTTCCTTACGAGGCGAAGAAGG-3P and 5P-GGTG-
CTGCTTGTTAGGAGGTCAAGTAAAGGGC-3P ; ornithine trans-
carbamylase (OTC) [8], 5P-GAGTTTTCAAGGGCATAGAATCG-
TC-3P and 5P-CAGATCTGCTGATAGCCAT-3P ; argininosuccinate
synthase (ASS) [9], 5P-CACAGCCCCGAGTGTGAATTTGTCC-3P
and 5P-AGTGACCTTGCTCTGGAGACGATGA-3P ; hepatocyte nu-
clear factor-4 (HNF-4) [10], 5P-CTGCTCGGAGCCACAAAGAG-
ATCCATG-3P and 5P-ATCATCTGCCACGTGATGCTCTGCA-3P ;
CCAAT/enhancer binding protein (C/EBP)-L [11], 5P-GCGCGA-
GCGCAACAACATC-3P and 5P-TGCTTGAACAAGTTCCGCAG-
3P), 200 WM deoxynucleoside triphosphates and 2 mM MgCl2 in a
DNA thermal cycler (Perkin Elmer, Norwalk, CT, USA). Following
2% agarose gel electrophoresis, ethidium bromide staining was per-
formed to detect the PCR products. The number of ampli¢cation
cycles for each target gene was adjusted according to the exponential
ampli¢cation of each control. The intensity of each PCR product
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relative to that ampli¢ed using the L-actin primer set was calculated
using a densitometric scanner taking the intensity of the control as 1.
2.4. Nitrite assay
Nitrite in the culture medium was measured using a modi¢ed Griess
reaction following the conversion of nitrate to nitrite by nitrate re-
ductase. Brie£y, 50 Wl of culture medium was mixed with 39 Wl
MOPS^EDTA (50 mM, pH 7.0), 10 Wl NADH (2 mM), and 1 Wl of
5 U/ml nitrate reductase. Following incubation for 3 h at room tem-
perature, 100 Wl of Griess reagent (0.5% sulfanilamide, 2.5% phos-
phoric acid, and 0.05% naphthylethylene diamine in H2O) was added
and incubated for 10 min at room temperature. Absorbance was as-
sayed at 550 nm and compared with a standard curve obtained using
sodium nitrite.
2.5. Determination of nuclear factor UB (NF-UB) activity by
electrophoretic mobility shift assay (EMSA)
For this assay, cells were plated in the maintenance medium with-
out EGF, and 24 h later, cells were treated with SB and/or EGF (50
ng/ml) for 1 h. Subsequently, nuclear extracts of cells were prepared
and protein concentrations in each sample were determined using the
Bio-Rad Bradford protein assay reagent. EMSA for NF-UB was per-
formed using the Promega gel shift assay system according to the
manufacturer’s instructions. The e¡ect of genistein (100 WM), an in-
hibitor of protein tyrosine kinases, on NF-UB activation was analyzed
by treating cells for 1 h prior to and during the treatment of SB and/
or EGF. A 100-fold molar excess of unlabelled oligonucleotide was
used as a speci¢c competitor.
2.6. Assay of urea synthesis
Cells previously incubated in a medium containing SB in either the
presence or absence of NOS inhibitors or NO donor for 48 h were
further incubated for 24 h in the same medium containing 20 mM
NH4Cl. Urea nitrogen level in the medium was colorimetrically de-
termined at 525 nm with Sigma kit no. 535. The medium containing
NH4Cl was incubated without cells as a negative control, and tested
in the same way to calculate the amount of urea synthesized. This was
calculated as nmol urea nitrogen per 106 cells for 24 h by counting
viable cells in each well.
2.7. OTC assay
Cells were harvested by scraping into mitochondria lysis bu¡er
(0.5% Triton, 10 mM HEPES, pH 7.4, 2 mM dithiothreitol), and total
protein was extracted by three freeze-thaw cycles. OTC enzyme activ-
ity was measured as previously described [12] with modi¢cations.
Brie£y, 30 Wg of total cellular protein was added to 700 Wl of reaction
mixture (5 mM ornithine, 15 mM carbamyl phosphate, and 270 mM
triethanolamine, pH 7.7) which was incubated at 37‡C for 30 min.
Reactions were stopped by adding 250 Wl of 3:1 phosphoric acid/
sulfuric acid (by volume). Citrulline production was then determined
by adding 50 Wl of 3% 2,3-butanedione monoxime, incubating at 95^
100‡C in the dark for 15 min, and measuring absorbance at 490 nm.
2.8. Statistical analysis
At least three independent determinations of each parameter were
compared among the treatment groups using two-sample Student’s
t-tests.
3. Results and discussion
3.1. Induction of iNOS expression and NO production
The induction of iNOS mRNA expression was evident at 6 h
from the start of the butyrate treatment as compared to the
control (Fig. 1A). Accordingly, butyrate treatment led to a
signi¢cant increase in the concentration of nitrite in the media
(Fig. 1B). This was prevented signi¢cantly by the simultane-
ous inhibition of NOS with inhibitors; the degree of inhibition
was greater by the speci¢c inhibitor AG than by a non-speci¢c
one, L-NAME (Fig. 1B). Exposure to an exogenous NO do-
nor, SNP, increased the nitrite concentration signi¢cantly
more than butyrate (Fig. 1B). The induction of iNOS expres-
sion in human hepatocytes by butyrate was shown for the ¢rst
time in this study, and these results are in agreement with the
previous observation that iNOS expression was increased by
the use of SB in Chinese hamster ovary cells which had been
transfected with the human iNOS cDNA [13]. Because iNOS
transcription is highly dependent on the activation of NF-UB
[14], this factor was evaluated by EMSA (Fig. 2A). Given that
our cells were maintained in a medium containing EGF which
was previously shown to induce NF-UB [15], we evaluated the
e¡ect of EGF on NF-UB activation in parallel with that of
butyrate. Butyrate-treated cells showed a shifted band of NF-
UB (Fig. 2A, media 3 and 7), which was absent in experiments
in which protein tyrosine kinase inhibitor genistein (Fig. 2A,
media 4 and 8) or a speci¢c competitor was added (Fig. 2A,
medium 3P). No expression of iNOS mRNA was seen in re-
sponse to butyrate in cells treated with genistein (Fig. 2B). In
comparison, EGF-treated cells demonstrated negligible NF-
UB activation when compared to control cells maintained in
a medium without EGF, and did not synergistically increase
NF-UB activation with butyrate (Fig. 2A, media 5 and 7).
Therefore, NF-UB activated by butyrate in our cells may
play a role in the induction of iNOS by butyrate.
3.2. E¡ects of NOS inhibition on urea-synthetic capacity
The results presented in Fig. 3 demonstrate that butyrate
treatment signi¢cantly increased the concentration of urea ni-
trogen in medium when compared to that of the control, and
that the simultaneous inhibition of NOS signi¢cantly in-
creased the urea-synthetic capacity as compared to that of
butyrate treatment alone. Moreover, in accordance with the
results of nitrite analysis, urea-synthetic capacity was further
increased by the treatment with AG than by L-NAME. In
comparison, the butyrate-induced increase of urea-synthetic
capacity was signi¢cantly attenuated by the treatment with
an exogenous NO donor. These ¢ndings suggest that the in-
Fig. 1. Butyrate-induced increase of iNOS mRNA expression and
nitrite production in immortalized human hepatocytes. A: Induction
of iNOS mRNA expression by SB (5 mM), which was analyzed by
RT-PCR. The ¢gure shows one representative experiment. B: Con-
centrations of nitrite in media after 24-h treatment with SB in the
presence or absence of NOS inhibitors or NO donor were deter-
mined by the Griess reaction. NAME 3 mM, AG 1 mM, SNP
0.5 mM. Data are expressed as the mean of three independent de-
terminations. Bars indicate S.D. *P6 0.05 compared with butyrate-
untreated control cells; #P6 0.05 compared with butyrate-treated
cells in the absence of NOS inhibitors and SNP.
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creased production of urea by butyrate was the net result of
the balance between the suppressive e¡ect through iNOS in-
duction and the di¡erentiating e¡ect as previously described
[6].
L-Arginine is the substrate of iNOS. It is also the natural
substrate of arginase in the urea cycle in which arginine is
converted to ornithine and urea is generated. Therefore, the
increase in urea production following iNOS inhibition could
be due to the increased availability of substrate for arginase.
However, it was recently shown that an exogenous NO donor
can also reduce urea synthesis in rat hepatocytes [16], a result
that was again demonstrated in human cells in this study.
Therefore, NO, generated either endogenously or exoge-
nously, may be detrimental to the urea-synthetic capacity of
hepatocytes induced by butyrate.
3.3. E¡ects of butyrate and NO on the expression of urea cycle
enzymes
Among urea cycle enzymes, OTC and carbamyl phosphate
synthetase are expressed in a tissue-speci¢c manner in the liver
and small intestine, whereas the expression of ASS and argi-
ninosuccinate lyase is not tissue-speci¢c and more or less
ubiquitous [17]. We analyzed the change of expression level
of OTC and ASS, each representative of tissue-speci¢c and
non-speci¢c ones, respectively, by RT-PCR. As shown in
Fig. 4A, expression of OTC was increased by butyrate. Ex-
pression of ASS, on the other hand, was evident even before
the butyrate treatment and slightly decreased after it, irrespec-
tive of NOS inhibition or exposure to an exogenous NO do-
nor. Therefore, the induction of OTC upon di¡erentiation by
butyrate may contribute to the increased urea-synthetic ca-
pacity in these cells. The level of OTC expression further in-
creased following simultaneous treatment with butyrate and
NOS inhibitors, while that of ASS did not change as com-
pared to that of butyrate treatment alone (Fig. 4A). Fig. 4B
demonstrates that the OTC activity itself was increased after
butyrate treatment and further increased by simultaneous
treatment with butyrate and NOS inhibitors. Therefore, the
augmentation of increase of urea synthesis by NOS inhibitors
could be due to an elevated level of OTC activity. It has been
shown that the mRNA level and activity of OTC, in contrast
to the other four urea cycle enzymes, decrease rapidly and
cannot be restored by hormones, such as glucocorticoid or
Fig. 2. NF-UB activation (A) and the e¡ect of its inhibition on the
iNOS mRNA expression (B) in butyrate-treated human hepatocytes.
A: Cells were plated in the maintenance medium without EGF, and
after 24 h, the medium was changed to one containing SB (5 mM)
and/or EGF (50 ng/ml). Nuclear extracts of cells were prepared
after 1 h, and EMSA for NF-UB was performed. The e¡ect of gen-
istein (100 WM) on NF-UB activation was analyzed by treating cells
for 1 h prior to and during the treatment with SB and/or EGF. A
100-fold molar excess of unlabelled oligonucleotide was used as a
speci¢c competitor (medium 3P). The shifted bands of media 3 and
7 are indicated by the arrowhead. B: Induction of iNOS mRNA ex-
pression by SB, which was analyzed by RT-PCR, was abolished by
the treatment with genistein.
Fig. 3. E¡ects of SB (5 mM) in the presence or absence of NOS in-
hibitors or NO donor on the urea synthesis of immortalized human
hepatocytes. 48 h after incubation in each indicated medium, cells
were further incubated in a supplemented medium containing 20 mM
NH4Cl for 24 h. The urea nitrogen in the medium was determined
colorimetrically at 525 nm. NAME 3 mM, AG 1 mM, SNP
0.5 mM. Data are represented as the mean of three independent de-
terminations. Bars indicate S.D. *P6 0.05 compared with butyrate-
untreated control cells ; #P6 0.05 compared with butyrate-treated
cells in the absence of NOS inhibitors and SNP.
Fig. 4. E¡ects of SB (5 mM) treatment for 48 h in the presence or
absence of NOS inhibitors or NO donor on the levels of mRNA ex-
pression of urea cycle enzymes, ASS and OTC, analyzed by RT-
PCR (A) and on the activity of OTC (B). NAME 3 mM, AG
1 mM, SNP 0.5 mM. A: The arbitrary units were calculated by
densitometric scanning of the intensity of each PCR product of
OTC relative to that ampli¢ed using the L-actin primer, taking the
intensity of the control as 1. The ¢gure shows one representative ex-
periment. B: OTC activity was determined by incubating total cellu-
lar protein with a reaction mixture (5 mM ornithine, 15 mM car-
bamyl phosphate, and 270 mM triethanolamine, pH 7.7) at 37‡C
for 30 min. Citrulline production was then determined by adding
3% 2,3-butanedione monoxime, incubating at 95^100‡C in the dark
for 15 min, and measuring absorbance at 490 nm. Data are pre-
sented as the mean of three independent determinations of OTC ac-
tivity (Wmol of citrulline/mg of protein). Bars indicate S.D.
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glucagon, in primary cultured rat hepatocytes put into culture
[18^20]. To our knowledge, the transcriptional induction of
OTC as a putative mechanism underlying the increased urea-
synthetic capacity of butyrate-induced hepatocytes has not
been previously demonstrated.
We next analyzed whether butyrate treatment or NOS in-
hibition changes the expression level of the transcription fac-
tors which regulate OTC expression, such as HNF-4 and
C/EBPL [17,21], by RT-PCR. The OTC enhancer was previ-
ously shown to be activated by a combination of HNF-4 and
C/EBPL, but not by either alone [21]. Fig. 5 demonstrates that
the expression of HNF-4 was increased by butyrate treatment
for 24 h, while that of C/EBPL was unchanged. Since OTC
expression was not detectable after the same period of buty-
rate treatment (data not shown) and only became evident
after 48 h (Fig. 4), this transcriptional induction of HNF-4
by butyrate is most likely to be responsible for the induction
of OTC transcription. However, because simultaneous NOS
inhibition did not further increase the HNF-4 expression, oth-
er mechanisms, not yet de¢ned, may also play a role in the
further increase of OTC expression by NOS inhibition. These
may include the activation of HNF-4 and/or C/EBPL by post-
translational modi¢cation such as phosphorylation/dephos-
phorylation [22], or the decrease of truncated C/EBPL which
is a potent inhibitor of C/EBP function [23], which still remain
to be determined by EMSA of these factors.
The level of OTC mRNA was also increased by treatment
with an exogenous NO donor as compared to that of butyrate
treatment alone (Fig. 4), while the butyrate-induced increase
of urea synthesis was signi¢cantly attenuated (Fig. 3). It was
previously demonstrated that NO may inhibit the hepatocyte-
speci¢c protein synthesis by a¡ecting a translational or post-
translational process [24]. Therefore, this increase of OTC
mRNA level by an exogenous NO donor is likely to be due
to the stabilization of its mRNA resulting from the transla-
tional inhibition, which needs to be further clari¢ed by nu-
clear run-on assay. Alternatively, since NO can directly inhibit
enzyme activities by interaction with SH- or metal-containing
groups [25], it is also plausible that the inhibition of urea-
synthetic capacity by NO may have resulted from the direct
inhibition of the activity of urea cycle enzymes.
In conclusion, increased NO production in the di¡erentia-
tion process of human hepatocytes by butyrate may play a
role in suppressing butyrate-induced urea-synthetic capacity.
Therefore, the inhibition of NO production in the process of
in vitro induction of hepatocyte-speci¢c di¡erentiation could
be a reasonable way to acquire more applicable hepatocytes
for the development of an e⁄cient bioarti¢cial liver.
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